Genotypic Resistance of Hepatitis B Virus to Lamivudine in Renal Transplant Recipients

Joh, Jae‐Won; Lee, H.H.; Park, J.W.; Lee, D.H.; Yoo, Byung Chul; Lee, K.W.; Kim, S.J.

doi:10.1016/j.transproceed.2004.11.037

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten studies did not present specific information on HBV genotypes, but could be assumed due to almost unique genotype pattern in the respective countries: Seven studies [Kim et al, 2003; Hong et al, 2004; Joh et al, 2005; Lee et al, 2005, 2006; Paik et al, 2006; Gwak et al, 2007] presenting 147 patients originated from Korea and were therefore assumed as genotype C. Two studies presenting 12 patients from Greece and Turkey [Economou et al, 2005; Pai et al, 2005] were assumed as genotype D [Norder et al 2004]. Ten patients from Poland presented by Gora‐Gebka et al 2007 were assumed to be genotype A [Deterding et al, 2008].…”

Section: Resultsmentioning

confidence: 99%

Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

Damerow

Yuen

Walker

et al. 2010

Journal of Medical Virology

View full text Add to dashboard Cite

Little is known about differences between individual hepatitis B genotypes and mutation patterns associated with lamivudine resistance. This study analyses the lamivudine‐associated mutation pattern in relation to the four major HBV genotypes A–D. The PubMed database was screened for keywords “HBV OR Hepatitis B,” “YMDD,” “genotype,” and “lamivudine”; all identified publications published till June 2009 were analyzed for differences in mutation pattern. To confirm the literature‐based findings the databases of two reference laboratories in Tübingen (Germany), and Melbourne (Australia) were analyzed. Twenty‐nine studies were identified reporting 827 patients with known hepatitis B genotype who underwent lamivudine treatment and developed resistance mutations. The literature data revealed that genotype A favors the rtM204V mutation unlike the other major genotypes (P < 0.001), which corresponds to a significant difference in the mutation pattern of genotypes endemic in Asian countries and those found in the rest of the world. These significant findings of the literature‐review could be reproduced in the analysis of the databases from Tübingen and Melbourne. Furthermore, the rtL180M mutation is significantly connected to the rtM204V mutation in genotypes A, B, and C, respectively. It is concluded that there is proof that HBV genotypes differ in their mutation pattern of lamivudine resistance. Future studies will need to evaluate whether this will translate into genotype‐specific differences in resistance emergence on either entecavir or telbivudine as these antivirals differ in their mutation profile, rtM204V for entecavir and rtM204I for telbivudine. J. Med. Virol. 82:1850–1858, 2010. © 2010 Wiley‐Liss, Inc.

show abstract

Section: Resultsmentioning

confidence: 99%

Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

Damerow

Yuen

Walker

et al. 2010

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Unfortunately, in the literature, there is a lack of data on the development of viral resistance among CKD, hemodialyzed patients, or transplant recipients. Only a very few observational studies using lamivudin have yet been published [69,70]. …”

Section: Hepatitis Bmentioning

confidence: 99%

Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients

Urbánek¹

2012

Kidney Blood Press Res

View full text Add to dashboard Cite

Within the last few decades, the incidence and prevalence of both hepatitis B and C infections have decreased among kidney disease patients. Significant advances have been made in the prevention of hepatitis B and C virus transmission in these high-risk populations; however, the transmission risk is still not negligible. Viral hepatitis infections represent a significant problem among kidney disease patients; patients on regular dialysis, as well as renal transplant recipients (RTRs) due to their epidemiological, virological, and clinical features. Chronic hepatitis B and C have a strong impact on the clinical course of kidney disease as well as on the clinical course after kidney transplantation. The purpose of this review is to focus on the epidemiology, transmission modes, natural courses, and treatment options of hepatitis B and C infections in both chronic kidney disease patients and RTRs.

show abstract

Genotypic Resistance of Hepatitis B Virus to Lamivudine in Renal Transplant Recipients

Cited by 2 publications

References 6 publications

Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients

Contact Info

Product

Resources

About